Making a model for ethical pharma work in the real world

9 May 2016

Achieving commercial success and leading new innovations at the same time as proving your credentials as ethical, patient-focused and community-minded is what so many big pharma companies are striving for.

The way that the independent French firm Pierre Fabre is structured makes not just striking a balance between those aims, but combining them, so much simpler.

Marc Alias, the company’s vice president of corporate communications, tells the Pharma Letter how this structure works, and how it is aimed at continuing the mission of the organization’s founder, Pierre Fabre, who died in 2013 and had described the company’s aim as “caring for the human being as a whole” by “placing pharmaceutical ethics at the very heart of our operations”.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK